PR95410

MOUNTAIN VIEW, Calif., April 11, 2022 /PRNewswire=KYODO JBN/ --

- Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management

and other VCs in oversubscribed funding round to accelerate Turn Bio's

preclinical advances in multiple therapeutic areas

Turn Biotechnologies, a cell rejuvenation company developing novel mRNA

medicines to cure untreatable, age-related conditions, today announced that it

closed an oversubscribed fundraising round to support the next stage of its

development.

Investments from two international pharmaceutical organizations and a venture

capital group associated with a third underscored widespread interest in Turn

Bio's unique cell rejuvenation therapy, which is built on the company's

proprietary ERA™ platform.

International pharmaceutical industry backing came from three groups:

    -- Astellas Venture Management LLC, a venture capital organization within

       Astellas Pharma, which is actively engaged in business as an

       R&D-driven global pharmaceutical company with the business philosophy

       to "Contribute toward improving the health of people around the world

       through the provision of innovative and reliable pharmaceutical

       products";

    -- Daewoong Pharmaceutical, recognized as one of the world's most

       collaborative pharmaceutical companies; and

    -- HanAll Biopharma, which is conducting innovative research in

       ophthalmology, immunology, oncology, neurology, and produces

       therapeutics in endocrine, circulatory and urological diseases.

"The attention and support Turn Bio is receiving from organizations around the

world shows the confidence companies have in our ability to utilize our

proprietary technology platforms to develop cures for now-untreatable

conditions that afflict millions of people globally," said CEO Anja Krammer.

"Turn Bio is closer to proving that cell rejuvenation will transform how

medicine treats human disease – and ultimately extends the human healthspan."

An executive from HanAll acknowledged the importance of Turn Bio's work.

"Many age-related diseases have long been significant areas of unmet patient

need," said Dr. Almira Chabi, chief medical officer and chief development

officer at HanAll Pharmaceutical International, a U.S. organization HanAll

created to strengthen its R&D. "Turn Bio's innovative platform may bring a

pivotal transformation to a wide array of therapeutic areas. HanAll is

committing support and investment to help realize the full potential of this

pioneering technology as Turn Bio advances to a new phase of growth."

The round also attracted investment from LongeVC, which is focused on

accelerating companies' development in the longevity space; ThreeD Capital,

which invests in disruptive technologies, and Vitality Healthspan Foundation.

Existing investors, Methuselah Fund, Formic Ventures and Shanda Group,

increased their investments this round.

ABOUT TURN BIOTECHNOLOGIES

Turn Bio is a pre-clinical-stage company focused on repairing tissue at the

cellular level. The company's proprietary mRNA platform technology, ERA™,

restores optimal gene expression by combatting the effects of aging in the

epigenome. This restores the cells' ability to prevent or treat disease, and

heal or regenerate tissue and will help to fight incurable chronic diseases.

The company is currently completing pre-clinical research on tailored therapies

targeting indications in dermatology and immunology, as well as developing

therapies for ophthalmology, osteo-arthritis and the muscular system. For more

information, see www.turn.bio .

FOR MORE INFORMATION, CONTACT:

Jim Martinez, rightstorygroup

jim@rightstorygroup.com or (312) 543-9026

SOURCE  Turn Biotechnologies